Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 870K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ørsted, D. D. Articles by Nordestgaard, B. G. Search for Related Content PubMed PubMed Citation Articles by Ørsted, D. D. Articles by Nordestgaard, B. G. Social Bookmarking                            What's this?

¹ Department of Clinical Biochemistry, Herlev University Hospital, University of Copenhagen, DK-2730 Herlev, Denmark
² Department of Clinical Biochemistry and ³ The Copenhagen City Heart Study, Bispebjerg University Hospital, University of Copenhagen, DK-2400 Copenhagen NV, Denmark
⁴ Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, DK-2100 Copenhagen Ø, Denmark

CORRESPONDENCE Børge Grønne Nordestgaard: brno{at}heh.regionh.dk

p53 is an important tumor suppressor, normally preventing cancer development via apoptosis. A genomic Arg72Pro substitution in the p53 protein has important influence on cell death via apoptosis, which could be beneficial. We therefore tested the hypotheses that this polymorphism influences longevity, survival after a cancer diagnosis, and risk of cancer in the general population. We examined a cohort of 9,219 participants ages 20–95 from the Danish general population with 100% follow-up. The overall 12-yr survival was increased in p53 Arg/Pro heterozygotes with 3% (P = 0.003) and in Pro/Pro homozygotes with 6% (P = 0.002) versus Arg/Arg homozygotes, corresponding to an increase in median survival of 3 yr for Pro/Pro versus Arg/Arg homozygotes. We also demonstrated an increased survival after the development of cancer, or even after the development of other life-threatening diseases, for Pro/Pro versus Arg/Arg homozygotes. The Arg72Pro substitution did not associate with decreased risk of cancer. In conclusion, in this large cohort from the general population, we show that a well-known functional single nucleotide polymorphism in the tumor suppressor p53 protein leads to increased longevity, but not to decreased risk of cancer. The increased longevity may be due to increased survival after a diagnosis of cancer or other life-threatening diseases.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Johansen, J. S., Bojesen, S. E., Mylin, A. K., Frikke-Schmidt, R., Price, P. A., Nordestgaard, B. G. (2009). Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. JCO 27: 572-578 [Abstract] [Full Text]  
• Fallin, M. D., Matteini, A. (2009). Genetic Epidemiology in Aging Research. J Gerontol A Biol Sci Med Sci 0: gln021v1-gln021 [Abstract] [Full Text]  
• Levi, B.P., Morrison, S.J. (2009). Stem Cells Use Distinct Self-renewal Programs at Different Ages. Cold Spring Harb Symp Quant Biol 0: sqb.2008.73.049v1-sqb.2008.73.049 [Abstract]  
• Rodier, F., Campisi, J., Bhaumik, D. (2007). Two faces of p53: aging and tumor suppression. Nucleic Acids Res 35: 7475-7484 [Abstract] [Full Text]  
• Orsted, D. D., Bojesen, S. E., Tybjaerg-Hansen, A., Nordestgaard, B. G. (2007). Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. JCB 177: i14-i14 [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS